The NIH Guidelines (NIH Guidelines for Research Involving Recombinant DNA Molecules) require the use of an Institutional Biosafety Committee (IBC) to oversee any activities that involve biohazardous materials, especially research activities that involve recombinant or synthetic nucleic acid molecules. When conducting research that uses recombinant DNA, investigators are responsible for obtaining IBC approval.
Examples of other activities in addition to recombinant DNA research that require IBC approval may include:
- infectious agents
- human or non-human-primate materials (body fluids, cell lines, tissues)
All applicable research activities must be reviewed by the IBC, regardless of the source of funding for the proposed project.
Greenville Health System is registered with the NIH’s Institutional Biosafety Committee Registration Management System (IBC-RMS).
GHS contracts with Western Institutional Review Board (WIRB) to provide IBC services.
In accordance with NIH protocol, GHS has appropriate personnel in place for: reporting to the IBC and the institution any significant problems, violations of the NIH Guidelines, and any significant research-related accidents or illnesses; developing emergency plans for handling accidental spills, personnel contamination, and laboratory accidents; and providing technical advice to Principal Investigators and the IBC on research safety procedures.
These or related questions or concerns regarding IBC services at GHS may be directed to Dr. Charles Gregory at email@example.com.
Questions regarding infection control may be directed to Dr. J. William Kelly at firstname.lastname@example.org.
For more information: